Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Entamoeba hystolytica Manipulates Host Ion Transport Proteins to Cause Cell Death

By LabMedica International staff writers
Posted on 06 Oct 2015
A team of molecular microbiologists has found that immunity to infection by the parasitic amoeba Entamoeba hystolytica could be induced in humans by using RNAi (interfering RNA) technology to block the genes controlling the activity of potassium ion transporter proteins.

Investigators at the University of Virginia (Charlottesville, USA) borrowed techniques usually used by cancer researchers to search for human genes that respond to interaction with E. More...
histolytica. They reported in the September 8, 2015, online edition of the journal Scientific Reports that they had used RNAi technology to create a library of bladder cancer cells with a multitude of independent, silenced genes. Populations of these cells were exposed to the parasite, and surviving cells were re-cultured and then exposed to the parasite again. After nine generations, cells were showing resistance to destruction by E. histolytica.

The genes of these resistant cells were analyzed with next-generation sequencing technology, which identified 281 candidate susceptibility genes. Bioinformatics analyses revealed that ion transporters were significantly enriched among these susceptibility genes, and that potassium (K+) channels were the most common transporter identified. Their importance was further supported by colon biopsy of humans with amebiasis that demonstrated suppressed K+ channel expression.

Inhibition of human K+ channels by genetic silencing, pharmacologic inhibitors, and with excess K+ protected diverse cell types from E. histolytica-induced death. Thus, it was apparent that contact with E. histolytica parasites triggered K+ channel activation and K+ efflux by intestinal epithelial cells, which preceded cell killing. Specific inhibition of Ca2+-dependent K+ channels was highly effective in preventing amebic cytotoxicity in intestinal epithelial cells and macrophages.

"There is a clear need for new drugs targeting E. histolytica," said senior author Dr. William A. Petri Jr., professor of internal medicine and pathology at the University of Virginia. "Right now there is a single antibiotic that works against this parasite. We know that eventually the parasite will develop resistance to the antibiotic and at that point there is no plan B. This could be the plan B - targeting the human genes that enable the parasite to cause disease."

Related Links:

University of Virginia



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.